Cetir Centre Medic

Barcelona 08029

0 studies enrolling now · 3 studies all time

What they study most

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Follicular Lymphoma, HER2 Mutations Breast Neoplasms, Peripheral T-cell Lymphoma, Urologic Neoplasms, Uterine Cervical Neoplasms, Uterine Neoplasms

Studies at this site

• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression — Completed
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations — Running, not enrolling
• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed